Borroto RV, Cortez SR, Aguilera MY, Jiménez TA

Language: Spanish
References: 23
Page: 1-12
PDF size: 271.55 Kb.

ABSTRACT

Introduction: Rheumatoid arthritis is a chronic, inflammatory, autoimmune and multisystemic disease that is difficult to treat and is a global public health problem.
Objective: To assess the effect of pulsed electromagnetic field therapy in rheumatoid arthritis.
Methods: A randomized, prospective, longitudinal study was conducted in 60 patients with a diagnosis of exacerbated rheumatoid arthritis, with moderate and high activity, and positive rheumatoid factor. All attended the natural and traditional medicine consultation of the Institute of Neurology and Neurosurgery between March and September 2017. The sample was divided into two groups of 30 patients. Those in the control group were given methotrexate, folic acid and ibuprofen. Members of the second group were given methotrexate, folic acid and pulsed electromagnetic fields. Rheumatoid factor, C-reactive protein, globular sedimentation rate, pain, and disease activity rate were evaluated before and after three months of treatment.
Results: For all parameters measured, a highly significant statistical difference (p ≤ 0.01) was obtained in favour of the group that used low frequency pulsed electromagnetic field. No adverse events were reported in patients in the second group, but adverse events were reported in those treated with ibuprofen.
Conclusions: Therapy with pulsed electromagnetic fields is effective and safe in the treatment of exacerbated rheumatoid arthritis, with moderate and high activity.

REFERENCES

1. Aletaha D, Neogi T, Silman A, Funovits J, Felson DT, Bingham CO, et al. Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis & Rheumatism. 2010; 62(9):2569-81.

2. Zeidler H. The need to better classify and diagnose early and very early rheumatoid arthritis. J Rheumatol. 2012; 39(2):212-7.

3. Anaya JM, Pineda Tamayo R, Gómez LM, Galarza Maldonado C, Rojas Villaraga A, Martin J. Artritis reumatoide: bases moleculares, clínicas y terapéuticas. Medellín: CIB, Universidad del Rosario, FUNPAR; 2006.

4. Cardiel MH, Rojas Serrano J. Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study. Clin Exp Rheumatol. 2002; 20(5):617-24.

5. Weiss JE, Ilowite N. Juvenile Idiopatic Arthritis. Rheum Dis Clin Am. 2007; 33(4): 441-70.

6. Silman AJ, Hochberg MC. Epidemiology of the rheumatic diseases. 2nd ed. Oxford: Oxford University Press; 2001.

7. Gibofsky A. Current therapeutic agents and treatment paradigms for the management of rheumatoid arthritis. Am J Manag Care. 2014 May; 20 (7Suppl): S136-44.

8. Avci AB, Feist E, Burmester GR. Biologicals in rheumatoid arthritis: current and future. RMD Open. 2015 Aug 5:1-8.

9. Ganesan KL, Gengadharan AC, Balachandran C, Manohar BM, Puvanakrishnan R. Low frequency pulsed electromagnetic field--a viable alternative therapy for arthritis. Indian J Exp Biol. 2009 Dec; 47(12):939-48.

10. Kumar VS1, Kumar DA, Kalaivani K, Gangadharan AC, Raju KV, Thejomoorthy P, Manohar BM, Puvanakrishnan R. Optimización de la terapia de campo electromagnético pulsado para el tratamiento de la artritis en ratas. Bioelectromagnética. 2005 Sep; 26(6): 431-9.

11. Bartoloni E, Shoenfeld Y, Gerli R. Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin. Arthritis Care Res. 2011; 63:178-83.

12. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012; 32:2045-51.

13. González A, Maradit H, Crowson C, Ballman K, Roger V, Jacobsen S, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis. 2008; 67:64-9.

14. Kahlenberg J, Fox D. Advances in the medical treatment of Rheumatoid Arthritis. Hand Clin. 2011; 27:11-20.

15. Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res. 2014 Apr; 2(4): 288-94.

16. Witte T. Methotrexate as combination partner of TNF inhibitors and tocilizumab. What is reasonable from an immunological viewpoint? Clin Rheumatol. 2015 Apr; 34(4): 629-34.

17. Durán ME, González Haba E, Herranz A, Pernía S. Farmacia Hospitalaria. 2002 Tomo 2 cap. 20:1472-80.

18. Guzmán R, Restrepo JF. Artritis reumatoide temprana. Rev Colomb Reumatol. 2002; 9: 171-5.

19. Anderson RJ. Rheumatoid Arthritis. Clinical and laboratory features. In Klippel JH. In Primer on Rheumatic Diseases. 12th Ed. Arthritis Foundation. Atlanta 2001; 218-25.

20. McFarlane JP, Foley SJ, de Winter P. Acute suppression of idiopathic detrusor instability with magnetic stimulation of the sacral nerve roots. Br J Urol. 1997; 80: 734–741.

21. Salvatore JR, Weitberg AB, Mehta S. Nonionizing electromagnetic fields and cancer: a review. Oncology (Williston Park), 1996; 10: 563–70.

22. Binhi V, Savin A. Effects of weak magnetic fields on biological systems: physical aspects. Phys Uspekhi. 2003; 46: 259–91.

23. Kawczyk Krupka A, Sieron A, Shani J. Biological effects of extremely low-frequency magnetic fields on stumlated macrophages J774-2 in cell culture. Electromagn Biol Med. 2002; 21: 141–53.